- $180.81m
- $20.73m
- $53.43m
U.S. STOCKS ON THE MOVE-Talen Energy, Gold miners, Stratasys
Brief: Invivyd Inc Receives Deficiency Letter From Nasdaq
Invivyd Inc reports results for the quarter - Earnings Summary
Invivyd Inc expected to post a loss of 34 cents a share - Earnings Preview
Invivyd Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, And Targets Near-Term Profitability
Brief: Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda (Pemivibart) Provided Substantial Protection From Symptomatic Covid-19 Versus Placebo Over Six Months Of Follow-Up, With No Additional Doses, In Immunocompetent Participants
Brief: Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311
Brief: Invivyd Announces Continued Neutralizing Activity of PEMGARDA Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
Brief: Invivyd Announces Results From 180-Day Exploratory Efficacy Analysis Of CANOPY Phase 3 Study
Invivyd Inc reports results for the quarter ended in June - Earnings Summary
Invivyd Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
Brief: Invivyd Announces Departure Of Jeremy Gowler As Interim CEO
Brief: Invivyd Announces General Alignment With FDA On EUA Pathway For Prevention, Treatment Of Symptomatic COVID-19
Invivyd Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
Brief: Invivyd Receives Healthcare Common Procedure Coding System Reimbursement Codes
Brief: Invivyd Names Jeremy Gowler As Interim CEO